- Works count
- 332
- Citation count
- 18,814
- H-index
- 38
- i10-index
- 123
Research interests
Publications
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
New England Journal of Medicine · 2024 · 10.1056/nejmoa2312117
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2023 · 10.1016/s0140-6736(23)00727-4
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
New England Journal of Medicine · 2021 · 10.1056/nejmoa2112435
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
The Lancet · 2019 · 10.1016/s0140-6736(18)32409-7
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 10.1056/nejmoa1810865
Current projects
No projects listed.